AXL mediates resistance to cetuximab therapy

The EGFR antibody cetuximab is used to treat numerous cancers, but intrinsic and acquired resistance to this agent is a common clinical problem. In this study we show that overexpression of the oncogenic receptor kinase AXL is sufficient to mediate acquired resistance to cetuximab in models of non-s...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Brand, Toni M., Iida, Mari, Stein, Andrew P., Corrigan, Kelsey L., Braverman, Cara, Luthar, Neha, Toulany, Mahmoud, Gill, Parkash S., Salgia, Ravi, Kimple, Randall J., Wheeler, Deric L.
Formato: Artigo
Idioma:Inglês
Publicado: 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4167493/
https://ncbi.nlm.nih.gov/pubmed/25136066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-0294
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares